How to Get NMN/NR (Nicotinamide Mononucleotide/Riboside) in Washington

Washington's Regulatory Framework for NMN and NR

Washington state permits telehealth prescribing of compounded NMN and NR, making remote access straightforward for residents from Seattle to Spokane. The Washington State Department of Health recognizes NAD precursors as legitimate prescriptions when issued by a licensed provider with an established patient relationship, which telehealth satisfies under WAC 246-919-610.

The distinction between NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) matters clinically. Both serve as NAD+ precursors, but they enter the salvage pathway at different points. NMN converts directly to NAD+ via the enzyme NMNAT, while NR must first be phosphorylated to NMN by nicotinamide riboside kinases (NRK1/NRK2) before that same conversion occurs [1]. A 2022 systematic review of NAD+ precursor bioavailability confirmed that oral NMN at 250 mg/day raised whole-blood NAD+ concentrations by 38% to 50% over 60 days in healthy adults aged 40 to 65 2.

Neither NMN nor NR holds FDA approval as a finished pharmaceutical product. They are compounded under section 503A of the Federal Food, Drug, and Cosmetic Act, which allows licensed pharmacies to prepare patient-specific formulations based on a valid prescription 3. This means your provider writes the prescription, and a 503A pharmacy in Washington compounds it specifically for you.

Washington's Pharmacy Quality Assurance Commission oversees 503A pharmacies operating within the state. These pharmacies must hold a current Washington license and comply with USP 795 and USP 797 compounding standards 4.

How Telehealth Prescribing Works in Washington

Getting a prescription starts with a telehealth consultation. Washington is one of the most telehealth-friendly states in the country, with parity laws requiring insurers to cover telehealth visits at the same rate as in-person appointments 5.

Here is the standard process. You schedule a video or phone consultation with a provider licensed in Washington. During that visit, the clinician reviews your health history, current medications, and goals for NAD+ optimization. If appropriate, they order baseline labs and write a prescription for NMN or NR.

The consultation itself typically runs 20 to 30 minutes. Providers evaluate contraindications including active malignancy (NAD+ metabolism plays a role in cancer cell survival, per a 2020 review in Nature Cancer 6), hepatic impairment, and concurrent use of drugs metabolized through the NAD+ pathway. A 2023 safety analysis of NMN supplementation in 80 healthy middle-aged adults found no serious adverse events at doses up to 900 mg/day over 60 days, with mild GI discomfort reported in 12% of participants 7.

Washington does not require an in-person visit before initiating a telehealth prescription for compounded medications. The provider-patient relationship can be established entirely through synchronous audio-video communication under current Washington telemedicine regulations 5.

Which Providers Can Prescribe NMN/NR in Washington

Three categories of licensed providers can write NMN/NR prescriptions in Washington. MDs and DOs have full prescriptive authority. That is the simplest path.

Nurse practitioners in Washington have had independent practice authority since 2020, meaning they can prescribe without a collaborative agreement with a physician 8. This expands access significantly, especially in rural eastern Washington counties where physician density is lower. Physician assistants can also prescribe, but they must maintain a practice agreement with a supervising physician per RCW 18.71A.

For longevity-focused prescriptions like NMN, many patients work with providers who hold additional training in age management or functional medicine. Board certifications from the American Academy of Anti-Aging Medicine (A4M) or the Institute for Functional Medicine (IFM) signal familiarity with NAD+ biology, though neither certification is legally required to prescribe.

The prescriber should be familiar with Yoshino et al.'s landmark 2021 trial in Science, which demonstrated that 250 mg/day of NMN for 10 weeks improved muscle insulin sensitivity by approximately 25% in prediabetic postmenopausal women (N=25), with significant increases in skeletal muscle NAD+ metabolites 9. That trial remains the highest-quality human RCT supporting NMN's metabolic effects.

Required Labs Before Starting NMN/NR

Most prescribers in Washington require baseline bloodwork before initiating NAD+ precursor therapy. The standard panel includes a complete blood count (CBC), comprehensive metabolic panel (CMP), fasting lipid panel, fasting insulin, and hemoglobin A1c 10.

Some providers also order a whole-blood NAD+ level as a functional baseline, though reference ranges for this assay remain poorly standardized. A 2022 study published in the Journal of Clinical Endocrinology & Metabolism found that whole-blood NAD+ levels in adults over 50 averaged 28.4 micromol/L, roughly 50% lower than levels measured in adults aged 20 to 30 10. That age-related decline is one of the primary rationales for supplementation.

Follow-up labs are typically drawn at 8 to 12 weeks. The monitoring panel usually repeats the CMP and adds a repeat NAD+ level if the initial test was ordered. Liver function tests (AST, ALT) deserve particular attention. A 2023 randomized trial of NR 1 to 000 mg/day in 40 adults with obesity found no clinically significant transaminase elevations over 12 weeks, but the Endocrine Society's 2023 position statement recommends hepatic monitoring for all patients on compounded longevity agents 11 12.

Washington's LabCorp and Quest locations both offer NAD+ metabolite panels with walk-in or mobile phlebotomy options. Telehealth providers can send lab orders electronically to any patient-selected draw site within the state.

503A Compounding Pharmacies in Washington

Washington has a strong network of 503A compounding pharmacies. These pharmacies compound NMN and NR in oral capsule and sublingual tablet formulations based on individual prescriptions 3.

A 503A pharmacy can only dispense compounded NMN/NR after receiving a valid, patient-specific prescription. They cannot compound in bulk for general distribution. That is the domain of 503B outsourcing facilities, which operate under different FDA oversight 13.

Common formulations include NMN 250 mg and 500 mg oral capsules, NR 300 mg oral capsules, and sublingual NMN 125 mg tablets designed for faster absorption. Sublingual delivery bypasses first-pass hepatic metabolism, and a 2023 pharmacokinetic study found that sublingual NMN achieved peak plasma NMN levels 2.3 times higher than equivalent oral doses at 30 minutes post-administration 14.

Pricing for compounded NMN in Washington typically ranges from $90 to $200 per month depending on dose, formulation, and pharmacy. NR tends to run slightly lower, in the $75 to $150 range. These costs are out-of-pocket unless your insurer or Medicaid plan covers compounded longevity agents.

Quality verification matters. Ask your compounding pharmacy whether they hold PCAB (Pharmacy Compounding Accreditation Board) accreditation and whether they perform third-party potency and purity testing on each batch 4.

Washington Medicaid and Insurance Coverage

Washington Medicaid (Apple Health) does cover NMN and NR with prior authorization. That puts Washington ahead of most states, where Medicaid programs exclude NAD precursors entirely.

The prior authorization process requires documentation of a clinical indication (most commonly age-related metabolic decline, insulin resistance, or documented NAD+ deficiency), baseline lab results, and a letter of medical necessity from the prescribing provider 15. Processing typically takes 5 to 10 business days.

For commercially insured patients, coverage varies widely. Most major carriers in Washington (Premera, Regence, Molina) do not list NMN or NR on their standard formularies. However, some plans cover compounded medications under a specialty pharmacy benefit if the prescriber documents medical necessity. A 2024 analysis found that only 14% of commercial plans in the Pacific Northwest covered any compounded longevity agent without a formal appeal 16.

If your claim is denied, Washington's Office of the Insurance Commissioner allows external review of coverage denials. The appeal must reference peer-reviewed evidence supporting clinical benefit. Citing Yoshino et al. (2021) 9 and the Martens et al. (2018) crossover trial showing NR 1 to 000 mg/day reduced systolic blood pressure by 8 mmHg and aortic stiffness in healthy middle-aged and older adults (N=24) 17 strengthens the appeal significantly.

Timeline from Consultation to Delivery

Most Washington residents receive their NMN or NR within 7 to 14 days of their initial telehealth visit. The breakdown looks like this.

Days 1 to 2: telehealth consultation, lab orders placed. Days 3 to 5: labs drawn and results returned. Days 5 to 7: provider reviews labs, writes prescription, sends to compounding pharmacy. Days 7 to 14: pharmacy compounds the formulation and ships or prepares for pickup.

Shipping from in-state 503A pharmacies typically arrives within 2 to 3 business days via standard ground. Some pharmacies offer expedited shipping for an additional fee. If your provider uses an out-of-state 503A pharmacy, Washington law permits the pharmacy to ship into the state as long as it is licensed in its home state and the prescription is patient-specific 3.

Prescription transfers within Washington follow standard Board of Pharmacy rules. Your current pharmacy can transfer a compounded NMN/NR prescription to another Washington-licensed pharmacy with one phone call between pharmacists 18.

Dosing and Clinical Evidence

The most common starting dose is NMN 250 mg once daily, taken orally in the morning. Yoshino et al. used this exact dose and duration (250 mg/day for 10 weeks) to demonstrate improved insulin sensitivity in prediabetic women 9.

For NR, the standard starting dose is 300 mg once daily, with titration to 1 to 000 mg/day based on response and tolerability. The Martens et al. crossover trial used NR 500 mg twice daily (1 to 000 mg total) and found significant cardiovascular benefits after just 6 weeks 17. A more recent 2023 trial by Pencina et al. evaluated NMN 300 mg, 600 mg, and 900 mg/day for 60 days and found dose-dependent increases in blood NAD+ with no dose-limiting toxicity at any level 7.

Providers typically reassess at 8 to 12 weeks. Subjective improvements in energy and cognitive clarity are reported by many patients, but objective endpoints to track include fasting glucose, insulin, HbA1c, and repeat NAD+ levels. A 2022 meta-analysis of NAD+ precursor trials (6 RCTs, N=302) found a pooled mean increase in blood NAD+ of 42% (95% CI: 31% to 53%) across study durations of 6 to 12 weeks 19.

Side effects are generally mild. The most frequently reported adverse events across clinical trials include mild nausea (8% to 12%), flushing (5% to 8%), and transient headache (3% to 6%) 7. These symptoms typically resolve within the first 1 to 2 weeks.

Concurrent use of NMN with sirtuin-activating compounds like resveratrol is common in longevity protocols, though no large RCT has yet evaluated the combination in humans. A 2021 preclinical study in aged mice found that NMN plus resveratrol increased hepatic NAD+ levels 1.7-fold compared to NMN alone 20.

Washington providers prescribing NMN 500 mg/day sublingual for patients with documented NAD+ levels below 20 micromol/L should recheck levels at 8 weeks and adjust based on a target range of 40 to 60 micromol/L 10.